the abcellera biologics ( acc ) company is a new and promising industry industry that is a major public health problem. it is a new and powerful technology technology that is based on partnerships that are centered around partnerships. we have developed a centralized business model where we invest in teams and facilities and provide access to these capabilities through partnerships. we believe that this is best done in a partnership model. we continue to invest in our platform and build capacity and build capacity, including almost doubling our headcount and acquiring key technologies including a proprietary humanized rodent platform and a bispecific engineering platform. we also secured funding for and began work on the buildup of cement cement andgm manufacturing capabilities. finally, we ended the year with nearly $600 million in cash and over 200 million in accounts receivable. this provides a strong cash position which we will execute our plan for future growth.